Based on these results, in April 2022, the EMA adopted the indication for atezolizumab monotherapy as adjuvant treatment after complete resection and adjuvant platinum-based chemotherapy, for patients with high-recurrence risk NSCLC with PD-L1≥50% and absence of EGFR or ALK driver gene alterations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.